A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.
about
Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationAddressing phenoconversion: the Achilles' heel of personalized medicine.Immunological response as a source to variability in drug metabolism and transport.Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.Pharmacokinetic variability of anticancer agents.Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeTherapeutic drug monitoring in cancer chemotherapy.Drug disposition in pathophysiological conditions.Indirect regulation of CYP2C19 gene expression via DNA methylation.Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.Drug metabolism and liver disease: a drug-gene-environment interaction.Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk.Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.CYP450 genotype and pharmacogenetic association studies: a critical appraisal
P2860
Q34204238-AF56E15A-6F7B-4CC9-85B6-0A8B01747F92Q34706677-7B597943-8BE5-4147-9295-4EDCEC24FBA5Q35023701-C3462A27-AF97-41DE-8E06-FBDBB89E7ED2Q35749503-08D240F5-54F5-4453-9388-0F63B9351C63Q35827661-8DA73FAB-93ED-4E4F-BECC-A4DA594179F4Q36146910-87BC1F2B-3AF8-447A-B70E-0A2E74EB700EQ36307008-798D48F7-D0F2-47EE-9402-363939FDC221Q36944006-9236628B-B555-421F-A89C-3EC38CD88B06Q37810220-52C774A9-1093-400B-BE8E-EFC5B821EE93Q38022659-0784709A-B3D8-46D5-89CB-49CA5292AB45Q38608601-A9EBA915-B170-48C6-ABF3-A0813858387AQ38803038-3E24FD83-1080-483E-A393-8D41E414AEBCQ38809021-1E711236-E013-4CC5-8240-1768FA913EEAQ39037269-3899EB18-E29A-487C-B821-D44C8FF22060Q41642334-6E16B600-D67B-4BE6-A484-21E1923E17D6Q43579724-18502692-8070-4801-8A91-9295ACCD1E19Q44353604-35D93182-D6E9-49DF-B919-EAB1E102B60FQ45939354-3E48B143-F500-48D1-A4A6-10EF5E41C91CQ47554139-C70F5C5C-C7A6-495D-AF1B-3E398E1C3864Q47600302-D8FFCD30-074E-4DDD-BE61-9C757BB79B5BQ50271114-1FDE2395-D0D8-4978-8277-5FA6268007ADQ53513271-1A1CA720-F699-4930-847D-74CA22D25439Q57585515-339CF670-3FAF-41B5-901B-9AE399549FFF
P2860
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A discordance of the cytochrom ...... patients with advanced cancer.
@ast
A discordance of the cytochrom ...... patients with advanced cancer.
@en
type
label
A discordance of the cytochrom ...... patients with advanced cancer.
@ast
A discordance of the cytochrom ...... patients with advanced cancer.
@en
prefLabel
A discordance of the cytochrom ...... patients with advanced cancer.
@ast
A discordance of the cytochrom ...... patients with advanced cancer.
@en
P2093
P2860
P1476
A discordance of the cytochrom ...... patients with advanced cancer.
@en
P2093
D A Flockhart
I Cherrouk
I W Wainer
J L Marshall
M L Williams
P Bhargava
P2860
P304
P356
10.1046/J.1365-2125.2000.00189.X
P407
P577
2000-05-01T00:00:00Z